<DOC>
	<DOCNO>NCT02598557</DOCNO>
	<brief_summary>This randomized phase IIb trial study well alternative dose exemestane surgery work treat postmenopausal patient stage 0-II estrogen positive breast cancer . Chemoprevention use drug keep breast cancer form come back . The use exemestane may treat early stage ( stage 0-II ) breast cancer . Comparing exemestane standard dose regimen versus two alternative , less frequent dose regimen may decrease undesirable symptom effective treat breast cancer .</brief_summary>
	<brief_title>Alternative Dosing Exemestane Before Surgery Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Non-inferiority percent change time serum estradiol level , adjust baseline level , follow four six week exemestane 25 mg give three time per week one time per week compare exemestane 25 mg daily dosing . SECONDARY OBJECTIVES : I . To assess safety toxicity . II . To support preventive activity exemestane investigate change Ki67 progesterone receptor ( PgR ) level tumor cell adjacent intraepithelial neoplasia benign histologic structure . III . To assess possible association estradiol level tissue circulate biomarkers . IV . To investigate possible pharmacogenetic marker . V. To assess drug level tissue sample . VI . To investigate tissue circulate proteomics profile . OUTLINE : Patients randomize 1 3 treatment arm . ARM I : Patients receive exemestane orally ( PO ) daily ( QD ) day 1-7 . ARM II : Patients receive exemestane PO QD day 1 , 3 , 5 . Patients also receive placebo PO QD day 2 , 4 , 6 , 7 . ARM III : Patients receive exemestane PO QD day 1 placebo PO QD day 2-7 . In arm , course repeat every 7 day 4-6 week absence disease progression unacceptable toxicity . Patients undergo surgery day 29-43 . After completion study treatment , patient follow 30-40 day .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Postmenopausal woman ( postmenopausal : age &gt; = 60 year , amenorrhea &gt; = 12 month , bilateral oophorectomy , woman hysterectomy follicle stimulate hormone [ FSH ] &gt; 30 IU/L &lt; 60 year old ) histologically confirm estrogen receptor ( ER ) positive ( &gt; = 10 % ) primary breast cancer stage T02 , N01 , Mx ; woman large tumor refuse chemotherapy ( chemo ) and/or endocrine neoadjuvant therapy eligible Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 ( Karnofsky &gt; = 70 % ) Leukocytes &gt; = 3,000/microliter Absolute neutrophil count &gt; = 1,500/microliter Platelets &gt; = 100,000/microliter Total bilirubin = &lt; 2 x institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 1.5 x institutional ULN Creatinine within normal institutional limit Ability understand willingness sign write informed consent document Body mass index ( BMI ) &lt; 18.5 Kg/m^2 Previous treatment breast cancer include chemotherapy endocrine therapy Women plan receive neoadjuvant therapy Participants may receive investigational agent History allergic reaction attribute compound similar chemical biologic composition exemestane Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Other coexist malignancy ( exclusion basal cell carcinoma skin squamous cell carcinoma ) diagnose last 2 year randomization History severe osteoporosis ( T score = &lt; 4 either spine hip ) , presence vertebral fracture Use hormone replacement therapy ( HRT ) last 30 day prior randomization Use chemopreventive agent ( selective estrogen receptor modulators [ SERM ] ) last 3 month Concomitant use cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inducer medication ( rifampicin , phenytoin , carbamazepine , phenobarbital , St. John 's wort )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>